Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q37532095

about

New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys Update on the treatment of type 2 diabetes mellitus Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Seasonal Variation in the Daily Urinary Sodium Excretion in Outpatients from the Morioka Region of Northern Japan A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Dapagliflozin Dapagliflozin for the treatment of type 2 diabetes: a review of the literature Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Dapagliflozin in patients with type 2 diabetes mellitus.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Changes in Type 2 Diabetes Mellitus Patients in German Primary Care Prior to (2006) and After (2010, 2014) Launch of New Drugs Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

P2860

Q26739475-A7111346-266B-43B3-A8F1-54742D5DB8BE Q26752815-1A90CD6E-CD72-46F3-A7B2-5FC124A7EC87 Q26782225-0F12A5B8-AE35-41E3-8481-D46EAD37DCBA Q28072939-7D41E039-D2BD-4F4A-9AC7-65872BFCA50F Q28073342-447EDE10-05E4-48E8-9849-36243C34C94D Q28079134-53D622D4-6D84-415D-A240-E5DDFB32C5A4 Q28080114-75104C39-256F-4961-87EC-C4AE316FC9A8 Q28082343-24986EDA-70CF-4AA3-B282-11C9BE6B9C15 Q28085593-1052D1B7-8A90-42EC-B5D9-C1BC3D5BE887 Q28553482-6B6183A8-2330-48E8-A74E-71E27F66D441 Q30248634-15796323-48D5-49D9-93F8-356420379124 Q31117903-F93A09E0-51DE-4BF8-81D9-933C6971FE10 Q32186373-815B21DC-125F-43A9-9E27-D42B736BA2E9 Q33166813-E6A5EDAB-0FEA-4697-BBE4-70C6DB3A1388 Q33633674-B6829CCC-AEA6-4842-9C4C-015ECC23A387 Q33732593-CE4BE807-1FC1-4FE2-BDA6-44759BADA817 Q33871321-E3FB4885-0636-4E26-924F-57B60C4C5A5B Q33874679-436DEEA9-669C-47BA-8546-232A6902B6E6 Q33913060-4F45259E-B6DE-425A-AFE9-6C96F0DC5F5E Q34198692-E4FFCE6F-D47F-4F0F-A537-9AB18F050155 Q34613015-3A79241C-DA68-49DD-8351-E0F51C65EB24 Q34710819-CF97EB9F-BB23-4D75-96AB-17762B4CDC48 Q34726437-696C711E-7992-4CB3-BBB6-23F328BB4612 Q34973750-4D526153-0EC6-48E7-B14D-1992DC20D249 Q35064363-80B64E37-D072-448F-8386-3EE23EBBFEEE Q35157497-5B141982-B52F-4069-B81A-FE768B4877FC Q35181821-ABBFAFAD-33D0-4F3C-8027-DB5608C6339F Q35528766-10A92F11-8DEC-49BC-9B2A-9A3FE153BB73 Q35780861-AEF8F202-8930-48E3-A293-332A03564B3B Q35887931-D1264871-5A6F-4840-B3DF-A1A496E3EDF1 Q36059244-F81EC76D-1D07-4200-84D2-283D8B26DC7E Q36277881-44599508-AB66-45E9-B214-BDA4E529674D Q36341246-FA38FA8E-53CA-4050-B9D5-06443E583063 Q36345951-13F822DB-2387-4B5E-B391-370B2BF904D4 Q36599869-019478E9-33E4-493E-B75C-46D42FA24C6F Q36638899-A8BDB6F2-3C8F-4A82-9E22-7832A284DC5C Q36712216-93FFF227-6494-4E78-BBB7-FF0F4DAA869D Q36820604-5F5EC16F-03BD-4013-8E75-8B790D2D8875 Q36851156-1B0715AD-8D12-4859-BC60-E2346F7FCE7A Q37075620-2C15B6BC-8213-4B9D-9CA5-4CB733CCFA01

P2860

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q37532095

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@en

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@nl

type

label

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@en

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@nl

prefLabel

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@en

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@nl

P1433

Q37532095-22076095-296C-40BC-9F99-CA7BE699E1E2

P1476

Q37532095-4B580F6E-C5F8-4BD3-AD91-5192671D214A

P2093

Q37532095-779D81AB-A7BF-4B7B-95B5-E7B462476B8D

Q37532095-9C4741D4-2CEF-490F-9499-452C157AF4F3

Q37532095-ED898A02-0F41-426B-8977-0B08419EA042

Q37532095-EFC8F771-59A7-4D06-8454-6B59310F72E4

Q37532095-FF2AE411-DBB1-4D11-9A80-7A62BB5CCAF5

P2860

Q37532095-0FA6DE00-E4AF-4B69-914A-02A8F8336BF6

Q37532095-1821C7B5-401E-4E52-AF97-89B554AC08A8

Q37532095-40BCDECE-5126-448A-91BC-9C71A64DF47E

Q37532095-4CACF88F-A73B-40FF-9E26-051AFA2E2022

Q37532095-4D52FF50-3EEE-4822-80B1-0858FEEDF6F4

Q37532095-4EC38EA3-A008-4327-8F9C-9107EB10CB73

Q37532095-54455F37-AF8F-4D6A-ABFD-5A2AC6EA9934

Q37532095-5559F8A2-B5BE-4776-8095-4C7CC41BED4A

Q37532095-754D99BC-9239-4E59-A22D-63164E2E4230

Q37532095-842788A9-2DDE-4A85-AAC4-8B7889233132

P304

Q37532095-A28432BE-6929-4182-8A6C-F8D840B9E567

P31

Q37532095-EF69189C-324E-49CD-8F03-5377F2A1A6B8

P356

Q37532095-C15AC6F2-B656-40CC-9E48-41976DB06C17

P433

Q37532095-119530EE-67EA-43E2-822D-8D2985F5828C

P478

Q37532095-0E0B3B2C-9499-4F59-969B-670D7482A6D5

P577

Q37532095-77C64862-79E0-4D37-98C0-DD642C3B94D3

P5875

Q37532095-14281236-215A-4AC5-9D25-C572AA311FB1

P698

Q37532095-52816967-2809-4F70-88FD-2DC5D8776526

P921

Q37532095-203639B4-A73C-491F-88F6-4C633E4ACBDD

Q37532095-2d19f074-9977-463e-aa64-2743913067e9

Q37532095-6EE4EB1F-8DF5-4E7A-A76A-B1FC90178CE0

P932

Q37532095-9EFD98CF-3936-445A-A92F-F1DBA9F4D6A4

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Dapagliflozin a glucose-regula ...... subjects with type 2 diabetes.

@en

P2093

B Leslie

http://www.w3.org/2001/XMLSchema#string

D de Zeeuw

http://www.w3.org/2001/XMLSchema#string

H J Lambers Heerspink

http://www.w3.org/2001/XMLSchema#string

J List

http://www.w3.org/2001/XMLSchema#string

L Wie

http://www.w3.org/2001/XMLSchema#string

P2860

Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus

Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury

Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

Composite renal endpoints: was ACCOMPLISH accomplished?

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

P304

853-862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12127

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236738436

http://www.w3.org/2001/XMLSchema#string

P698

23668478

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3906841

http://www.w3.org/2001/XMLSchema#string